Cardiovascular Systems — Investor Day (August 2022)
84 slides from Cardiovascular Systems's investor day presentation, Aug 3, 2022
Slide 1: Capital Markets Day August 3, 2022
Capital Markets Day August 3, 2022
Slide 2: Welcome
Welcome Jack Nielsen Vice President, Investor Relations & Corporate Communications
Slide 3: Q4 FY22 Financial Results
O04 FY22 Financial Results Dy) CARDIOVASCULAR
Slide 4: Company Overview
Capital Markets Day – August 3, 2022 Company Overview Scott R. Ward Chairman, President & Chief Executive Officer
Slide 5: Forward Looking Statements Safe Harbor
Forward Looking Statements Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 6: Financial Disclaimers
Financial Disclaimers Financial Information This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI’s independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may l
Slide 7: Regulatory Disclaimers
Regulatory Disclaimers Product Availability Diamondback 360® Coronary Orbital Atherectomy System FDA-approved. Available for sale in the U.S. Diamondback 360® Peripheral Orbital Atherectomy System FDA-cleared. Available for sale in the U.S. Diamondback 360® Peripheral Orbital Atherectomy System – Ex
Slide 8: Committed to getting people back to what matters
Committed to getting people back to what matters
Slide 9: Vision and Mission
Vision To eliminate cardiovascular disease as a barrier to living a full life by providing awareness and access to quality treatment. Mission Saving Limbs. Saving Lives. Every Day. Patient Centric and Customer Focused Cardiovascular Systems, Inc. 700,000 Over 700,000 patients worldwide successfully
Slide 10: CSI Board of Directors
CSI Board of Directors Sachin H. Jain, M.D. Director since 2021 Scott R. Ward Chairman, President & CEO Director since 2013 Kelvin Womack Director since 2020 Martha G. Aronson Director since 2017 Erik Paulsen Director since 2019 William Cohn, M.D. Director since 2015 Stephen Stenbeck Director since
Slide 11: CSI Today
CSI Today 2 Manufacturing facilities (St. Paul, Minn. and Pearland, Texas) Serving patients in 31 Countries worldwide 750 Employees 100 Engineers and Scientists Over 300 U.S. Patents and Patents pending
Slide 12: Key Goals
Key Goals Analyst Day: 2018 Innovation Launch 20 New Products Global Expansion Deliver $25M - $50M in FY23 Grow the Core Business Achieve 10% growth in the core business
Slide 13: Grow and protect the core while we expand into larger markets
Grow and protect the core while we expand into larger and faster growing markets Focused Transformation Grow and protect Expand global OAS franchises Focused on our complex coronary and peripheral patient population Leveraging the capacity and competency of our U.S. sales channel Innovation to pursu
Slide 14: Grow and Protect
Highly differentiated and proprietary orbital atherectomy technology Grow and Protect Executing core growth initiatives, improving commercial execution and near-term product pipeline 01 Proven strategy to drive higher revenue per OAS procedure 02 Adoption of OAS internationally remains strong03
Slide 15: Strategy Expands Total Addressable U.S. Markets to $18.8B
Strategy Expands Total Addressable U.S. Markets to $18.8B Innovation: Pursuing Larger and Faster Growing Markets $18.8B $9.2B TAM HEMODYNAMIC SUPPORT HR-PCI $9.6B $800M TAM PERIPHERAL & CORONARY DCB $8.8B $6.6B TAM THROMBECTOMY PAD & VTE $2.2B PERIPHERAL AND CORONARY OAS AND IVL
Slide 16: Financial Outlook Summary
Financial Outlook Summary Long-term revenue growth fueled by execution of new platform development into large, high-growth markets 5 Year CAGR of 17% Significant investments in product development and clinical research Attractive and stable gross margins Long-term, sustainable profitability achieved
Slide 17: Today's Agenda
Today’s Agenda 01 Grow & Protect Global OAS Franchises Scott Ward, Chairman, President & CEO 02 Expanding Product Portfolio Dramatically Increases TAM Matt Cambronne, Vice President, Research & Development 03 Growth Summary & Financial Projections Jeff Points, Chief Financial Officer 04 Closing Comm
Slide 18: CSI Leadership
CSI Leadership John M. Hastings Executive Vice President, Operations & Technology Robert T. Beverly Vice President & General Manager, Peripheral Sales Harrison T. Boyd II Vice President & General Manager, Coronary Sales Jack E. Nielsen Vice President, Investor Relations & Corporate Communications Je
Slide 19: Grow and Protect Core OAS Business
Grow and Protect Core OAS Business Scott R. Ward Chairman, President and Chief Executive Officer
Slide 20: Core OAS Business
US PERIPHERAL US CORONARY INTERNATIONAL Orbital Atherectomy and Interventional Support Devices in the US and International markets Core OAS Business 7% FY22 Revenue: $16.4M OAS: $16.4M OAS Device Sales in: • Japan • Europe • Asia Pacific • Canada • ROW 66% FY22 Revenue: $155.3M OAS: $149.7M ISD: $5.
Slide 21: Leadership in medical evidence
Leadership in medical evidence Durable patient outcomes Over 83,000 Patients Treated WW in FY22 OAS Has Transformed the Care of Complex Patients Best-in-class professional education Over 700,000 patients Treated with orbital atherectomy since 2007 Innovation Exceptional clinical support
Slide 22: Excellence in Quality and Manufacturing
Committed to Partnering with our Customers with the Highest Quality Products, Services and Relationships Excellence in Quality and Manufacturing Scalable and continuous COGS reductions (volume and materials costs) to protect OAS margins from ASP declines Manufacturing Initiatives Sourcing and Supply
Slide 23: Customer Service and Relationships are a Core Competitive Advantage
Customer Service and Relationships are a Core Competitive Advantage US Commercial Sales US Sales Organization Summary 01 02 03 04 05 Deep Clinical Acumen Case Support and Medical Education Long Tenure and Historically Low Turnover Durable Relationships Built on Successful Outcomes Exceptional Sales
Slide 24: Orbital Atherectomy for peripheral & coronary arterial disease
Orbital Atherectomy for treating peripheral & coronary arterial disease Strong Fundamentals Large, underserved markets High unmet medical need and economic cost OAS is highly differentiated – over 200 patents Partnering with Customers to treat complex cases Robust medical evidence A patient is treat
Slide 25: Unprecedented Evidence in Treating Arterial Calcium
Unprecedented Evidence in Treating Arterial Calcium Leadership in Medical Evidence Trial Size Importance Peripheral LIBERTY 360° (3-year Data) n=1,204 • “All-comers” trial, any treatment option • Nearly 700 Rutherford Class 4-6 patients enrolled OPTIMIZE (Enrollment Complete) n=66 • OAS + DCB vs. DC
Slide 26: The Diamondback 360 Advantage for Calcified Coronary Artery Disease
The Diamondback 360® Advantage for Calcified Coronary Artery Disease Robust Medical Evidence: Proven Performance Consistently high rates of procedure success Low rates of procedural complications across large study populations TLR rate of 3.4% at one year in the DES Subset 1. Chambers J, et al. JACC
Slide 27: LIBERTY OAS Sub-analysis
LIBERTY 360 OAS Sub-analysis (n=503) High Freedom from TVR & Major Amputation at 3 Years 1. CSI Data on File 2. Giannopoulos S, et al. J Endovasc Ther. 2020;27(5):714-725 RC 2-3 RC 4-5 RC 6 RC 2-3 RC 4-5 RC 6 Freedom from TVR/ TLR at 3 Years1 Kaplan-Meier Estimate Freedom from Major Limb Amputation
Slide 28: Evolving to Become a Broad-Based PAD Business
Evolving to Become a Broad-Based PAD Business Peripheral Executive Summary Innovation and Portfolio Advancement Accelerate Revenue per Procedure • Leveraging ISD portfolio, launching differentiated new products and providing case coverage Restore Growth in Core OAS Drive Market Expansion and OAS ado
Slide 29: Prevent Amputations by Accelerating Patient Access to Care
Prevent Amputations by Accelerating Patient Access to Care Catalysts for Market Expansion and Growth Market Expansion Broaden Call Points Professional Education • Train 200 new customers per year • Offer advanced procedural training • CLI pathway education • Outcomes and efficiency optimization • Va
Slide 30: Reimbursement Continues to Stabilize
CMS 2023 proposed rules weighted average impact on CSI procedures increase by 1% Reimbursement Continues to Stabilize AMA CPT Code Restructure (OBL non-facility, Physician) • LER codes are not on September CPT Panel Agenda. Delays push effective date to 2025 or beyond CMS CY2023 Proposed Physician F
Slide 31: Strategy for building high volume OBL accounts
Strategy for building high volume OBL accounts focused on the care of complex PAD Customized Outpatient Resources – Comprehensive Resources to support high volume OBLs: Pricing Programs Inventory Management Consulting Product Portfolio Claim Assistance Patient Access to Care Clinical Support Profess
Slide 32: Innovation and Portfolio Enhancement
Full Leg Revascularization Embolic Protection Radial and Pedal Access ATK Mixed Plaque Robust portfolio of options to treat multi-level peripheral disease Innovation and Portfolio Enhancement Exchangeable Series with GlideAssist® Launched 2019 2.0 Max Crown Mixed Plaque Device Launch 2023 Extended L
Slide 33: Full Portfolio of Balloons, Catheters and Guidewires
Full Portfolio of Balloons, Catheters and Guidewires Leverage scale: 60,000 cases performed in FY22 Accelerate Revenue per Procedure ViperCross™ Support Catheter Zilient® Peripheral Guidewire Launched 2022Launched 2021 Launched 2019 JADE® OTW and Sapphire® 1.0 mm Balloons Shepherd™ Peripheral Guidew
Slide 34: Peripheral Growth Outlook
Peripheral Growth Outlook ISD Growth Estimate: ~40% Core OAS Growth Estimate: Mid-Single Digits Strive to become a $230M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure OBL Reimbursement 60,000 Patients treated in FY22 Tailwinds Levera
Slide 35: Coronary Executive Summary
A trusted partner in the treatment of complex coronary artery disease Coronary Executive Summary Restore growth in Core OAS with focus on lesion segmentation Leverage imaging adoption to drive market expansion and vessel preparation with OAS Expansion of medical evidence with ECLIPSE Improve commerc
Slide 36: Lesion Segmentation
Assuring orbital atherectomy is the treatment of choice for properly selected patients Lesion Segmentation Serving Unique Market Needs Treatment Algorithms Have Formed Balloon Crossable Concentric Short Focal Uniform Single Vessel Uncrossable Eccentric Long Diffuse Nodular Multivessel disease
Slide 37: Imaging: A Catalyst for Market Expansion
Imaging leads to 28% increase in vessel preparation 1 Imaging: A Catalyst for Market Expansion and Growth Diagnosis Enables physicians to accurately identify calcium and calcium morphology for patient selection and case planning. Increasing Diamondback utilization Assessment Enables physicians and C
Slide 38: Grow and Protect the Coronary Business
Grow and Protect the Coronary Business Improve Commercial Execution and Focus Reinforce safety data, Versatility, Efficiency and Diamondback Advantage to Capture Cases Leverage Full Portfolio using ISDs, Lesion Targeting, Clinical Acumen and Advanced Techniques to Support Customers Professional educ
Slide 39: Expanding the Coronary Complex Portfolio
Expanding the Coronary Complex Portfolio Accelerate ISD Growth Teleport® Microcatheter Launched 2022 Launched 2019 Scoreflex® NC Sapphire® NC24 Specialty catheters for chronic total occlusions Launch 2023 Sapphire® ExpansionSapphire® Balloons ViperWire Advance® with Flex Tip Launched 2019 ISD Revenu
Slide 40: Coronary Growth Outlook
Coronary Growth Outlook ISD Growth Estimate: Mid-20% Core OAS Growth Estimate: Mid-Single Digits Strive to become a $100M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure 14,000 Patients treated in FY22 Tailwinds Leveraging the Full Por
Slide 41: International Executive Summary
Rapidly increasing scale in International markets International Executive Summary $1.8M $16.4M FY18 FY19 FY20 FY21 FY22 Focused on Established Market Opportunities in Coronary Commercial Execution Through Focused Distribution Network A large, underpenetrated market opportunity for OAS: 4.5 million O
Slide 42: Focused on Coronary in Japan, EU and ROW
Focused on Coronary in Japan, EU and ROW Commercial Execution Key Drivers Longer Term OpportunitiesGeographic Priorities Invest in high-impact Market Development customized for select target markets Scalability – expand business capabilities/processes & leverage technologies to accelerate growth Pro
Slide 43: International Growth Outlook
Significant Growth opportunity in International Markets International Growth Outlook Core OAS Growth Estimate: Mid-20% Strive to become a $50M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure Tailwinds Enter the China Market Emerging Me
Slide 44: Core Business Growth Vectors
Orbital Atherectomy and Interventional Support Devices in the US and International markets Core Business Growth Vectors US PERIPHERAL FY27: ~$230M US CORONARY FY27: ~$100M INTERNATIONAL FY27: ~$50M OAS Device Sales in: • Japan • Europe • Asia Pacific • Canada • ROW OAS devices: Diamondback, Stealth,
Slide 45: Expanding Product Portfolio Dramatically Increases TAM
Expanding Product Portfolio Dramatically Increases TAM Matt Cambronne Vice President, Research & Development
Slide 46: Strategy Expands Total Addressable U.S. Markets to $18.8B
Strategy Expands Total Addressable U.S. Markets to $18.8B Diversification Accelerates Growth $18.8B $9.2B TAM HEMODYNAMIC SUPPORT HR-PCI $9.6B $800M TAM PERIPHERAL & CORONARY DCB $8.8B $6.6B TAM THROMBECTOMY PAD AND VTE $2.2B PERIPHERAL AND CORONARY OAS AND IVL
Slide 47: Product Portfolio Expands into New Segments
Product Portfolio Expands into New Segments *Prototype products and components are depicted, actual commercial embodiments may vary Product FY22 FY23 FY24 FY25 FY26 FY27 Orbital Atherectomy 2.00 Max Crown OAS Next Generation Coronary Interventional Support Devices Coronary Scoring Balloon CTO Toolki
Slide 48: New Atherectomy & ISD Products
New Atherectomy & ISD Products OrbusNeich ® Scoreflex ® NC • First non-compliant scoring balloon in the US. Highest rated burst pressure in the US. Intended for in-stent restenosis, mixed plaque, ostial and bifurcated lesions • Initiated launch in Q3 FY22. Commercial performance has exceeded expecta
Slide 49: Thrombectomy
so MMM, Thrombectomy = >>> ie CARDIOVASCULAR
Slide 50: Venous ThromboEmbolism
Venous ThromboEmbolism Deep Vein Thrombosis (DVT) Deep Vein Thrombosis (DVT) occurs when a blood clot forms in one or more deep veins, usually in the legs. When a clot formed in deep veins travels to the lungs and blocks the main pulmonary artery or its branches, it causes a Pulmonary Embolism (PE)
Slide 51: US Thrombectomy Market Opportunity
US Thrombectomy Market Opportunity FY27 FY22 Mechanical Pump-based Aspiration Catheter-directed thrombolysis Mechanical = 20%+ CAGR Mechanical = ~15% CAGR FY22-FY27 Market Size FY27 FY22 Mechanical Pump-based Aspiration Catheter-directed thrombolysis FY22-FY27 Market Size Analyst Estimates, Company
Slide 52: Thrombectomy System Product & Indications
Application PE, PV PE, PV PE PE Configuration Straight, 45o Curve Straight, 30o Curve Straight, 20o Curve Straight, 10 o Curve Thrombectomy System Product & Indications System consists of a mechanical clot retrieval device and aspiration catheter Initial indication for removal of thrombus from perip
Slide 53: Competitive Advantage
Competitive Advantage Removed Simulated Soft Clot Aspiration Catheter • Low-profile, navigable design with atraumatic tip • Sizes and curves shapes will address needs across the spectrum of PE and peripheral vascular anatomy Mechanical Retriever • Laser-cut retrieval basket designed for optimizing c
Slide 54: Clinical / Regulatory Strategy
Clinical / Regulatory Strategy Preliminary Study Designs Indication N Design Endpoints DVT ~130 Single Arm, Prospective, Post- Market Study • Acute Thrombus Removal • Adverse Events/PTS Severity @ 30 days PE ~120 Single Arm, Prospective Multicenter Pivotal Study • Percent reduction in RVLV ratio @ 4
Slide 55: Intravascular Lithotripsy
M Intravascular Lithotripsy = >>> —FE
Slide 56: Intravascular Lithotripsy
Intravascular Lithotripsy The technology has since been miniaturized and used in a variety of catheter-based interventions, including treatment of calcified peripheral and coronary arteries High-energy waves including shockwaves have been used in the body for decades for diverse therapeutic uses in
Slide 57: US IVL Market Opportunity
US IVL Market Opportunity 20%+ CAGR FY27 FY22 ATK/Iliac BTK FY27 FY22 Coronary Coronary IVLPeripheral IVL FY22-FY27 Market SizeFY22-FY27 Market Size 15%+ CAGR ~$215M $600M-700M+ ~$80M PAD (-80% ATK) $150M-200M Total PAD (~75% ATK) Analyst Estimates. Company Estimates
Slide 58: IVL System Balloon Configurations
IVL System Balloon Configurations Coronary Peripheral ATK/Iliac Peripheral BTK Lengths 12 mm 20 mm 60 mm 40 mm Diameter 2.5 – 4.0 mm 4.0 – 8.0 mm 2.5 – 5.0 mm Guidewire Config RX OTW OTW Product & Indications System consists of a console-based generator, connector and portfolio of catheters Three ba
Slide 59: Competitive Advantage
Competitive Advantage Electrode test in fluid bath Product design targets • Improved crossing profile • Enhanced deliverability • Wider range of balloon sizes • Greater number of pulses per catheter for more efficient treatment • Simplified system set-up • Improved balloon durability CSI • Large and
Slide 60: IVL Clinical/Regulatory Strategy
Product FY22 FY23 FY24 FY25 FY26 FY27 Peripheral (ATK/BTK) Coronary IVL Clinical/Regulatory Strategy Preliminary Study Designs Indication N Design Endpoints Peripheral (ATK & BTK) ~120 Multi-center, Prospective Single-arm • Freedom from MAEs at 30 days • Angiographic success (i.e., residual stenosis
Slide 61: Drug Coated Balloons
M Drug Coated Balloons — >>> —*5
Slide 62: US Drug Coated Balloon Market Opportunity
US Drug Coated Balloon Market Opportunity FY27 FY22 Peripheral ATK DCB $0M FY27 FY22 Coronary ISR DCB 60%+ CAGR (FY24-FY27) Coronary DCBPeripheral DCB FY22-FY27 Market SizeFY22-FY27 Market Size ~15% CAGR ~$200M $350M-$400M $150M-$200M Analyst Estimates, Company Estimates
Slide 63: Drug Coated Balloons Product & Indications
Drug Coated Balloons Product & Indications • A portfolio of Everolimus coated balloons intended to treat coronary and peripheral arterial disease • Initial coronary indication will be for the treatment of in-stent restenotic (ISR) lesions • Initial peripheral indication will be for the treatment of
Slide 64: Mechanical Circulatory Support
Mechanical Circulatory Support
Slide 65: US High Risk PCI Support Market Opportunity
US High Risk PCI Support Market Opportunity FY27 FY22 High Risk PCI pVAD 15%+ CAGR High Risk PCI Mechanical Circulatory Support FY22-FY27 Market Size United States Coronary Artery Disease1 16.7 Million Annual PCI procedures (excludes CABG) 2 ~1 Million Addressable Market3 400k+ Est. Procedures FY22
Slide 66: Mechanical Circulatory Support (MCS)
Mechanical Circulatory Support (MCS) Product & Indications • System consists of a disposable micro-axial flow pump catheter and controller, a reusable console, a custom delivery guide wire and a custom introducer kit • Initial indication and use in high-risk PCI procedures to support left ventricula
Slide 67: Focused on Complex Cardiovascular Disease: CSI Product Portfolio
Focused on Complex Cardiovascular Disease CSI Product Portfolio 2.0 Max Crown - Mixed Plaque Device Vipercath XC, ViperCross & Teleport Catheters WIRION EPD Peripheral IVL Balloons Peripheral Everolimus DCB Thrombectomy: Aspiration Catheters and Clot Retrievers Diamondback & Stealth Diamondback - Ex
Slide 68: Growth Summary & Financial Projections
Growth Summary & Financial Projections Jeffrey S. Points Chief Financial Officer
Slide 69: Financial Outlook Summary
Financial Outlook Summary Long-term revenue growth (5 Yr CAGR of 17%) primarily fueled by execution of pipeline products into very large, high-growth markets Attractive gross margins • OAS • ISDs & International • Pipeline Significant investments in product development and clinical research Long-ter
Slide 70: Key Investments Fuel Revenue Growth
Key Investments Fuel Revenue Growth Investments in growth platforms… 65% 27% 8% FY23 43% 21% 9% 27% FY27 Global Base Business Peripheral Coronary International New Platform Products Revenue Contribution 57% 25% 10% 8% FY25 FY23 FY25 FY27 Revenue $255M - $265M $325M - $350M $500M - $550M CAGR (at mid
Slide 71: Investing In Large, High-Growth Markets
Investing In Large, High-Growth Markets Targeting large, high growth markets fuels ~17% 5 Yr CAGR $0 $100 $200 $300 $400 $500 $600 FY23 FY25 FY27 High Growth Moderate Growth Lower Growth Drug Coated Balloons Intravascular Lithotripsy Thrombectomy Mechanical Circulatory Support International Atherect
Slide 72: Long Range Outlook: Key Assumptions
Long Range Outlook: Key Assumptions Outlook Assumes: Inflation normalizes in FY23 Platform product revenues in U.S. only Outlook Does Not Assume: COVID and related impacts A global recession Reimbursement changes New M&A activity
Slide 73: Gross Margin
Gross Margin TailwindsHeadwinds Impact of inflation on component and freight costs Modest ASP declines Increased mix of lower margin ISDs and International revenue Direct OAS cost reduction programs Increasing volumes New platform products include higher margin profile
Slide 74: Research & Development
Research & Development Significant investments range from 14% - 17% of revenue TailwindsHeadwinds Investments in clinical trials related to new platform products and geographic markets Higher mechanical circulatory support development costs Outsourcing development costs for new platform products Com
Slide 75: SG&A
SG&A Incremental leverage drives SG&A spend down to approximately 55% of revenue in FY27 TailwindsHeadwinds Increased costs associated with several major product launches New sales channel for Pulmonary Embolism Thrombectomy product Improved sales rep productivity with new product launches Increased
Slide 76: Capital Allocation
Capital Allocation Strong balance sheet with no long-term debt Disciplined organization focused on prioritizing and managing spending New platform product transactions begin H2 FY23 Strong banking relationships Current cash position of $160 million provides resources necessary to fund new platform p
Slide 77: Financial Outlook Summary
Financial Outlook Summary Long-term revenue growth (5 Yr CAGR of 17%) primarily fueled by execution of pipeline products into very large, high-growth markets Attractive gross margins • OAS • ISDs & International • Pipeline Significant investments in product development and clinical research Long-ter
Slide 78: Closing Comments
Capital Markets Day – August 3, 2022 Closing Comments Scott R. Ward Chairman, President & Chief Executive Officer
Slide 79: Closing summary: leadership, growth and platforms
79 • Leadership in Atherectomy • Sequential momentum, improving commercial execution & competitiveness • Organic growth & globalization • Rapid growth in ISD sales • New products: 2.0 Max, ScoreFlex and the CTO Toolkit • Core competence in Quality, Manufacturing, R&D and Commercialization • Grow and
Slide 80: Transformation Drives Accelerating Growth
Transformation Drives Accelerating Growth $- $100 $200 $300 $400 $500 $600 FY22A FY27E New PlatformsInternationalU.S. Coronary FranchiseU.S. Peripheral Franchise $ in millions $500M - $550M CAGR ~17%
Slide 81: Key Investment Merits
Key Investment Merits Restore revenue growth and deliver key milestones in FY23 Strong sequential growth and momentum in our Core OAS business Improving commercial execution and focus New products: 2.0 Max Crown, ScoreFlex NC and the CTO Toolkit Driving higher revenue per OAS procedure New product p
Slide 82: Meeting the Needs of our Key Stakeholders
Meeting the Needs of our Key Stakeholders Cardiovascular Systems, Inc. Guided by our Mission Focused on complex peripheral and coronary artery disease Expanding TAM nearly ten-fold with new product platforms Financially strong with the team and talent to win Serving Over 250,000 Patients with $500-$
Slide 83: Q&A Session
Capital Markets Day – August 3, 2022 Q&A Session CSI Executive Team
Slide 84: Trademarks
CSI®, Diamondback®, Diamondback 360®, GlideAssist®, Stealth 360®, Take a Stand Against Amputation®, ViperWire®, ViperWire Advance®, Wirion®, Zilient®, Diamondback 360 Precision™, Propel™, Shepherd™, ViperCath™ ViperCross™ and COR™ are trademarks of Cardiovascular Systems, Inc. © 2022 Cardiovascular